Back to All Specialties
59 Clinical Tools

Oncology Calculators & Scores

Performance status (ECOG/KPS), cancer staging, prognostic scores, and chemotherapy dosing.

Oncologyadditional-nodal-metastasis-nomogram

Additional Nodal Metastasis Nomogram

Predicts probability of additional non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy

Calculate Online
Oncologyalbi-grade

ALBI (Albumin-Bilirubin) Grade for Hepatocellular Carcinoma (HCC)

Predicts survival in hepatocellular carcinoma patients based on objective measures of liver function (albumin and bilirubin)

Calculate Online
Oncologyasymptomatic-myeloma-prognosis

Asymptomatic Myeloma Prognosis

Predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis

Calculate Online
Oncologybclc-staging

Barcelona-Clinic Liver Cancer (BCLC) Staging Classification

Determines disease progression and appropriate treatment course for hepatocellular carcinoma (HCC) patients. The BCLC staging system integrates tumor characteristics, liver function status, and performance status to classify patients into five stages (0, A, B, C, D) with specific treatment recommendations for each stage.

Calculate Online
Oncologybed-eqd2

BED / EQD2

Biologically effective dose and equivalent dose in 2-Gy fractions.

Calculate Online
Oncologybmv-model

Brain Metastasis Velocity (BMV) Model

Calculates rate of distant brain failure after stereotactic radiosurgery for brain metastasis to predict overall survival

Calculate Online
Oncologycarboplatin-calvert-dose

Carboplatin Dose (Calvert)

Carboplatin dose by the Calvert formula.

Calculate Online
Oncologycarg-tt

Cancer and Aging Research Group Chemotherapy Toxicity Tool (CARG-TT)

The CARG-TT estimates the risk of severe chemotherapy-related side effects (Grade 3 or greater toxicity) in older cancer patients (age >65). It uses 11 geriatric assessment variables, laboratory values, and patient characteristics to predict chemotherapy toxicity risk.

Calculate Online
Oncologychemotherapy-dose-bsa

Chemotherapy Dose (BSA-based)

BSA-based chemotherapy dosing using Du Bois formula.

Calculate Online
Oncologycisne

Clinical Index of Stable Febrile Neutropenia (CISNE)

Identifies febrile neutropenia patients at low risk for serious complications. Used for adult outpatients with solid tumor, fever ≥38°C (100.4°F), and neutropenia (≤500 cells/mm³ or ≤1,000 cells/mm³ with expected decrease to 500).

Calculate Online
Oncologycrash-score

Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) Score

Assesses the risk of severe chemotherapy toxicity in older cancer patients (≥70 years). Predicts both hematologic (grade 4) and nonhematologic (grade 3/4) toxicities based on patient characteristics and chemotherapy regimen.

Calculate Online
Oncologycrs-grading

Cytokine Release Syndrome (CRS) Grading

Assesses severity of cytokine release syndrome in immunotherapy patients, particularly those receiving CAR-T cell therapy and other immune effector cell therapies. CRS is an acute inflammatory process marked by a spectrum of clinical symptoms and substantial elevations of serum cytokines.

Calculate Online
Oncologyctcae

Common Terminology Criteria for Adverse Events (CTCAE) v5.0 - Hematologic

Grades severity of hematologic and lymphatic adverse events from cancer treatment using standardized criteria. Assesses anemia, neutropenia, thrombocytopenia, and other blood disorders according to laboratory values and clinical presentations.

Calculate Online
Oncologydamico-risk-classification

D'Amico Risk Classification for Prostate Cancer

Assesses 5-year risk of treatment failure in patients with localized prostate cancer based on clinical factors. Stratifies patients into low, intermediate, or high-risk groups to guide treatment decisions and prognosis estimation.

Calculate Online
Oncologydelta-p-score

Dutch-English LEMS Tumor Association Prediction (DELTA-P) Score

Predicts small-cell lung cancer (SCLC) in patients with Lambert-Eaton myasthenic syndrome (LEMS) using clinical parameters assessed at or within 3 months of onset. The score helps identify high-risk patients requiring intensive cancer screening.

Calculate Online
Oncologyebmt-transplant-score

EBMT (Gratwohl) Transplant Risk Score

Pre-transplant risk score for allogeneic HSCT (0-7).

Calculate Online
Oncologyecog-karnofsky-converter

ECOG-Karnofsky Performance Status Converter

Bidirectional conversion between ECOG and Karnofsky scales.

Calculate Online
Oncologyecog-performance-status

Eastern Cooperative Oncology Group (ECOG) Performance Status

Determines patient's ability to tolerate therapies in severe illness, specifically for chemotherapy. Simple 5-point scale that describes patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability.

Calculate Online
Oncologyelts-score

ELTS Score (EUTOS Long-Term Survival)

CML long-term survival risk score.

Calculate Online
Oncologyeqd2

EQD2 - Equivalent Dose in 2 Gy Fractions

Converts a radiotherapy schedule to equivalent dose in 2 Gy fractions.

Calculate Online
Oncologyfong-clinical-risk-score

Fong Clinical Risk Score for Colorectal Cancer Recurrence

Predicts recurrence and survival risk for colorectal cancer patients with liver metastases after hepatic resection. Developed from analysis of 1,001 consecutive cases to identify high-risk patients who may benefit from adjuvant therapy or closer surveillance.

Calculate Online
Oncologygail-model-breast-cancer-risk

Gail Model for Breast Cancer Risk

Estimates risk for breast cancer based on demographic and clinical data. The Gail Model calculates a woman's absolute risk of developing invasive breast cancer over the next 5 years and up to age 90 (lifetime risk) using personal medical and reproductive history and family history of breast cancer among first-degree relatives.

Calculate Online
Oncologygalad-model-hcc

GALAD Model for Hepatocellular Carcinoma (HCC)

Diagnoses HCC based on serum biomarkers in patients with chronic liver disease (CLD). The GALAD model combines Gender, Age, AFP-L3, AFP, and DCP (des-gamma-carboxy prothrombin) to provide superior diagnostic accuracy compared to individual biomarkers.

Calculate Online
Oncologygi-gpa

Graded Prognostic Assessment for Gastrointestinal Cancer (GI-GPA)

Estimates survival in patients with gastrointestinal cancers and brain metastases. Uses 4 prognostic factors to provide risk stratification and guide treatment decisions for patients with brain metastases from GI cancers.

Calculate Online
Oncologyglasgow-prognostic-score

Glasgow Prognostic Score (GPS)

Inflammation and nutrition-based prognostic score for cancer patients using serum C-reactive protein and albumin levels. Predicts overall survival and disease-free survival across multiple cancer types including colorectal, hepatocellular carcinoma, sarcoma, and lung cancer.

Calculate Online
Oncologyimdc-risk-model

IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma

Predicts survival in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapy and assists in treatment selection based on risk stratification

Calculate Online
Oncologyimmune-related-adverse-events-endocrine-diabetes

Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus

Grades severity of hyperglycemia secondary to immune checkpoint inhibitor therapy and provides management recommendations

Calculate Online
Oncologyimmune-related-adverse-events-endocrine-hypothyroidism

Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism

Grades severity of hypothyroidism secondary to immune checkpoint inhibitor therapy and provides management recommendations

Calculate Online
Oncologyimmune-related-adverse-events-gi-colitis

Immune-Related Adverse Events for GI Toxicity - Colitis

Grades severity of colitis secondary to immune checkpoint inhibitor therapy and provides management recommendations

Calculate Online
Oncologyimmune-related-adverse-events-gi-hepatitis

Immune-Related Adverse Events for GI Toxicity - Hepatitis

Grades severity of hepatitis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates liver function tests including AST, ALT, and total bilirubin levels to determine the severity of immune-mediated hepatitis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, hepatology consultation needs, and monitoring for life-threatening complications. ICPi-induced hepatitis has an incidence of 5-10% in single-agent therapy but severe toxicity occurs in less than 2% of cases. The calculator provides evidence-based management recommendations essential for oncologists, hepatologists, and multidisciplinary teams managing patients on immunotherapy.

Calculate Online
Oncologyimmune-related-adverse-events-lung-pneumonitis

Immune-Related Adverse Events for Lung Toxicity - Pneumonitis

Grades severity of pneumonitis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates respiratory symptoms, oxygen requirements, and functional impact to determine the severity of immune-mediated pneumonitis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, pulmonology consultation needs, and monitoring for life-threatening respiratory complications. ICPi-induced pneumonitis has an incidence of 2.7% for all-grade and 0.8% for high-grade pneumonitis in single-agent therapy. The calculator provides evidence-based management recommendations essential for oncologists, pulmonologists, and intensive care teams managing patients on immunotherapy.

Calculate Online
Oncologyimmune-related-adverse-events-renal-nephritis

Immune-Related Adverse Events for Renal Toxicities - Nephritis

Grades severity of nephritis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates serum creatinine levels, renal function changes, and clinical symptoms to determine the severity of immune-mediated nephritis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, nephrology consultation needs, and monitoring for life-threatening renal complications. ICPi-induced nephritis has an incidence of 1-2% in single-agent therapy and 4.5% in combination therapy, with median onset at 14 weeks (range 6.5-21 weeks). The calculator provides evidence-based management recommendations essential for oncologists, nephrologists, and multidisciplinary teams managing patients on immunotherapy.

Calculate Online
Oncologyirecist-response

iRECIST Response (Immunotherapy)

Simplified iRECIST response classification for solid tumors on immunotherapy.

Calculate Online
Oncologykarnofsky-performance-status

Karnofsky Performance Status Scale

Determines patient's ability to tolerate therapies in serious illness, specifically for chemotherapy. This validated functional status scale ranges from 100% (normal, no evidence of disease) to 0% (death) and correlates with treatment tolerance, survival, and quality of life in cancer patients.

Calculate Online
Oncologykhorana-risk-score

Khorana Risk Score for Venous Thromboembolism in Cancer Patients

Predicts VTE risk for cancer patients depending on cancer type and other factors. This validated risk assessment tool helps identify cancer patients at high risk for venous thromboembolism who may benefit from thromboprophylaxis during chemotherapy treatment.

Calculate Online
Oncologyleibovich-2018-rcc

2018 Leibovich Model for Renal Cell Carcinoma (RCC)

Predicts progression-free and cancer-specific survival in patients with renal cell carcinoma (RCC) using clinical, surgical, and pathologic factors

Calculate Online
Oncologylent-prognostic-score

LENT Prognostic Score for Malignant Pleural Effusion

Predicts survival in patients with malignant pleural effusion using clinical and laboratory parameters to help inform treatment decisions and prognosis discussions

Calculate Online
Oncologylung-cancer-tnm-8th

Lung Cancer TNM Staging (8th Edition)

IASLC 8th edition TNM stage grouping for non-small cell lung cancer.

Calculate Online
Oncologymekhail-extension-motzer-score

Mekhail Extension of the Motzer Score

Predicts survival of metastatic renal cell carcinoma, more accurately than the original Motzer Score by incorporating additional prognostic factors

Calculate Online
Oncologymetroticket-hcc

Metroticket Calculator for Hepatocellular Carcinoma (HCC) Survival

Predicts 3 and 5-year survival after liver transplantation for patients with hepatocellular carcinoma (HCC), especially those not meeting Milan Criteria. Uses tumor size, number, and vascular invasion status.

Calculate Online
Oncologymirels-criteria

Mirels' Criteria for Prophylactic Fixation

Predicts risk of pathologic fracture in patients with long bone metastasis to guide prophylactic fixation decisions

Calculate Online
Oncologymodified-glasgow-prognostic-score

Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes

Provides improved cancer prognosis over the original Glasgow Prognostic Score, based on serum biomarkers (CRP and albumin) reflecting systemic inflammation and nutritional status

Calculate Online
Oncologymodified-recist

Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

Assesses treatment response in hepatocellular carcinoma (HCC) patients based on viable tumor enhancement, specifically designed for patients receiving targeted therapies and locoregional treatments.

Calculate Online
Oncologymskcc-motzer-score

Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)

Predicts survival based on clinical and laboratory data in metastatic RCC patients

Calculate Online
Oncologyneutropenia-grade-ctcae

CTCAE Neutropenia Grade

CTCAE neutropenia grading from the absolute neutrophil count (ANC): Grade 1 (<LLN-1500), Grade 2 (<1500-1000), Grade 3 (<1000-500), Grade 4 (<500 /mm³). Standard oncology toxicity grading for chemotherapy decisions and growth-factor support.

Calculate Online
Oncologynottingham-prognostic-index

Nottingham Prognostic Index (NPI)

Nottingham Prognostic Index (Haybittle 1982) for primary breast cancer: NPI = 0.2 × tumor size (cm) + lymph-node stage (1-3) + histologic grade (1-3). Bands: ≤2.4 excellent, 2.41-3.4 good, 3.41-4.4 moderate, 4.41-5.4 poor, >5.4 very poor. Implemented from the published paper (AGPL source repo not copied).

Calculate Online
Oncologypack-years

Pack-Years — Smoking Burden / Lung Screening

Pack-years quantify lifetime smoking exposure: (cigarettes per day / 20) x years smoked. >=20 pack-years is the USPSTF 2021 lung-cancer screening threshold (ages 50-80).

Calculate Online
Oncologypalliative-prognostic-score

PaP Score — Palliative Prognostic Score

The PaP score estimates 30-day survival probability in advanced solid-tumor patients from 6 variables (dyspnea, anorexia, KPS, clinician prediction, WBC, lymphocyte %). Total 0-17.5.

Calculate Online
Oncologypegfilgrastim-dosing

Pegfilgrastim Dosing (per Label)

Pegfilgrastim (Neulasta) dosing per FDA label: adults 6 mg SC once per chemotherapy cycle, ≥24 hours after cytotoxic chemotherapy and ≥14 days before the next cycle. Pediatric weight bands: <10 kg 0.1 mg/kg, 10-20 kg 1.5 mg, 21-30 kg 2.5 mg, 31-44 kg 4 mg, ≥45 kg 6 mg.

Calculate Online
Oncologyperitoneal-cancer-index

Peritoneal Cancer Index (PCI)

Peritoneal Cancer Index (Sugarbaker): 13 abdominopelvic regions each scored by largest lesion — LS-0 none, LS-1 <0.5 cm, LS-2 0.5-5 cm, LS-3 >5 cm or confluence; total 0-39. Higher = greater tumor burden; guides cytoreduction/HIPEC decisions.

Calculate Online
Oncologypet-tlg

PET Total Lesion Glycolysis (TLG)

Total lesion glycolysis: metabolic tumor volume multiplied by mean SUV. Prognostic PET metric in oncology.

Calculate Online
Oncologyprognostic-index-cancer-outcomes

Prognostic Index for Cancer Outcomes

Predicts cancer mortality from serum biomarkers using C-reactive protein (CRP) and white blood cell (WBC) count. This simple two-parameter scoring system provides risk stratification for cancer patients and helps guide prognostic discussions and clinical decision-making across multiple cancer types.

Calculate Online
Oncologypromise-score-malignant-pleural-effusion

PROMISE Score for Malignant Pleural Effusion

Predicts 3-month mortality in patients with malignant pleural effusion using clinical and biological parameters. This validated prognostic tool combines patient characteristics, performance status, laboratory values, and treatment history to provide accurate risk stratification and guide clinical decision-making for patients with malignant pleural effusion.

Calculate Online
Oncologyprostate-tumor-volume-density

Prostate Tumor Volume & Density

Calculates prostate volume using ellipsoid formula and PSA density to help distinguish between benign prostatic hyperplasia (BPH) and prostate cancer. This tool assists in biopsy decision-making, risk stratification, and treatment planning for patients with elevated PSA levels.

Calculate Online
Oncologypsa-doubling-time-calculator

PSA Doubling Time (PSADT) Calculator

Calculates PSA doubling rate in prostate cancer patients with biochemical recurrence after treatment. This prognostic tool correlates with survival and helps guide treatment decisions for salvage therapy, imaging studies, and castration-resistant disease management. Uses longitudinal PSA measurements to determine the rate of PSA increase over time.

Calculate Online
Oncologyr-iss-myeloma

R-ISS

Revised International Staging System for multiple myeloma.

Calculate Online
Oncologyradiation-pneumonitis-constraints

Radiation Pneumonitis Dose Constraints

QUANTEC-based lung dose constraint check: mean lung dose and V20 vs symptomatic pneumonitis risk.

Calculate Online
Oncologyspinal-instability-neoplastic-score

Spinal Instability Neoplastic Score (SINS)

Spinal Instability Neoplastic Score (SINS): quantifies spinal instability in patients with spinal metastases across 6 components (location, pain, bone lesion, alignment, vertebral collapse, posterolateral involvement). Total 0-18; higher scores indicate greater instability and need for surgical consultation.

Calculate Online
Oncologyucsf-capra-score

UCSF-CAPRA Prostate Cancer Risk Score

UCSF Cancer of the Prostate Risk Assessment (CAPRA, Cooperberg 2005): 0-10 point preoperative score predicting prostate cancer recurrence/ progression risk from PSA, Gleason pattern, clinical stage, age, and percent positive biopsy cores. 0-2 low, 3-5 intermediate, 6-10 high risk.

Calculate Online

Clinical Decision Support (CDS) Notice & Legal Disclaimer

All calculations and clinical scoring tools in this directory are intended strictly for educational and decision-support use by licensed medical practitioners. They do not constitute autonomous medical advice or direct treatment orders. See the full DexaMed Medical Disclaimer.